Literature DB >> 12829433

Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity.

Mark E Dunlap1, Steve Bibevski, Terrone L Rosenberry, Paul Ernsberger.   

Abstract

Parasympathetic control of the heart is attenuated in heart failure (HF). We investigated possible mechanisms and sites of altered vagal control in dogs with HF induced by rapid pacing. Muscarinic blockade reduced the R-R interval by 308 ms in controls but only by 32 ms in HF, indicating low levels of resting vagal tone. Vagomimetic doses of atropine sulfate prolonged the R-R interval by 109 ms in controls and increased standard deviation of the R-R interval by 66 ms but only by 46 and 16 ms, respectively, in HF. Bradycardia elicited by electrical stimulation of the vagus nerve was also attenuated in the HF group. Conversely, muscarinic receptor activation by bethanechol, and indirectly by neostigmine, elicited exaggerated R-R interval responses in HF. To investigate possible mechanisms, we measured muscarinic receptor density (Bmax) and acetylcholinesterase activity in different areas of the heart. In sinoatrial nodes, Bmax was increased (230 +/- 75% of control) and acetylcholinesterase decreased (80 +/- 6% of control) in HF. We conclude that muscarinic receptors are upregulated and acetylcholinesterase is reduced in the sinus node in HF. Therefore, reduced vagal control in HF is most likely due to changes of presynaptic function (ganglionic), because postsynaptic mechanisms augment vagal control in HF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829433     DOI: 10.1152/ajpheart.01051.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  19 in total

Review 1.  Evidence for impaired vagus nerve activity in heart failure.

Authors:  Steve Bibevski; Mark E Dunlap
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

2.  Autonomic Dysregulation as a Therapeutic Target for Acute HF.

Authors:  Anju Bhardwaj; Mark E Dunlap
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-10

Review 3.  Myths and realities of the cardiac vagus.

Authors:  J H Coote
Journal:  J Physiol       Date:  2013-07-22       Impact factor: 5.182

4.  Augmented fear bradycardia in rats with heart failure.

Authors:  Satoshi Koba; Ichiro Hisatome; Tatsuo Watanabe
Journal:  J Physiol Sci       Date:  2019-07-30       Impact factor: 2.781

5.  Decreased adrenoceptor stimulation in heart failure rats reduces NGF expression by cardiac parasympathetic neurons.

Authors:  Wohaib Hasan; Peter G Smith
Journal:  Auton Neurosci       Date:  2013-12-04       Impact factor: 3.145

6.  Autonomic regulation device therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Ahmed Bendary; Mohamed Bendary; Mohamed Salem
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

7.  Exercise training preserves vagal preganglionic neurones and restores parasympathetic tonus in heart failure.

Authors:  Marcelo H A Ichige; Carla R Santos; Camila P Jordão; Alexandre Ceroni; Carlos E Negrão; Lisete C Michelini
Journal:  J Physiol       Date:  2016-08-29       Impact factor: 5.182

8.  Post-exercise heart rate recovery independently predicts mortality risk in patients with chronic heart failure.

Authors:  Yi-Da Tang; Thomas A Dewland; Detlef Wencker; Stuart D Katz
Journal:  J Card Fail       Date:  2009-08-05       Impact factor: 5.712

9.  Unilateral vagus nerve stimulation improves ventricular autonomic nerve distribution and functional imbalance in a canine heart failure model.

Authors:  Juan Sun; Yanmei Lu; Yan Huang; Najina Wugeti
Journal:  Int J Clin Exp Med       Date:  2015-06-15

10.  Deregulation of hepatic insulin sensitivity induced by central lipid infusion in rats is mediated by nitric oxide.

Authors:  Nicolas Marsollier; Nadim Kassis; Karima Mezghenna; Maud Soty; Xavier Fioramonti; Amélie Lacombe; Aurélie Joly; Bruno Pillot; Carine Zitoun; José Vilar; Gilles Mithieux; René Gross; Anne-Dominique Lajoix; Vanessa Routh; Christophe Magnan; Céline Cruciani-Guglielmacci
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.